Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that a thyroid hormone receptor ẞ subtype-selective thyromimetic was effective in promoting hair growth in mouse and monkey models when applied topically.

This study found that adjusting plant growth conditions, such as the use of elicitors like yeast extract and methyl jasmonate, increased wedelolactone production in Eclipta alba cell suspension culture.

This study found that the synthesized compound 7b exhibited higher 5α-reductase inhibitory activity, increased solubility, and dissolution compared to finasteride, suggesting its potential as a lead compound for benign prostatic hyperplasia treatment.

Cortexolone 17a-propionate may be an effective new treatment for hair loss.

This study reports the discovery of LX-38, a novel non-steroidal drug candidate that may offer safer treatment for conditions like Benign Prostatic Hyperplasia by avoiding hormonal side effects associated with current therapies.

This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

This study explored the solubility and crystal structure of GI197111X, a 5-alpha reductase inhibitor for androgenetic alopecia, finding its solubility in Capmul MCM suitable for a soft gel dosage form.

This study found that novel androgen antagonists incorporating a carborane moiety showed anti-androgenic activity comparable to flutamide in a laboratory setting.

This study identified the N-(iodopropenyl) derivative 13 as a promising candidate for development as a radioiodinated androgen receptor ligand due to its binding affinity.

This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.

This study found that combining the natural product cedrol with minoxidil can improve the treatment of androgenetic alopecia by reducing the minoxidil dose needed, while a new nanocarrier system enhances drug delivery and effectiveness at hair follicles.

This study highlights the potential of polymeric micelles in enhancing the targeted delivery and efficacy of treatments for androgenetic alopecia, by offering improved retention on the scalp, extended release, and reduced systemic side effects compared to conventional therapies like minoxidil and finasteride.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study suggests that bioactives like Curcumin, Quercetin, and "Tulsi" may relieve chemotherapy-induced adverse drug reactions in cancer patients, potentially reducing resistance and recurrence.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

A new compound was made that might help treat diseases related to male hormones.

This study found that androsterone glucuronate (ADT-G) was the only androgenic metabolite sensitive to detecting differences between adult women with acne and controls, and its levels decreased with systemic treatment.

This source discusses a Phase 2 trial by Hu et al. that evaluated the efficacy of topical GT20029 compared to a placebo, though the abstract does not provide specific results.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study reported that after 7.5 months of treatment, topical Alfatradiol significantly increased anagen hair rates in women and men with androgenetic alopecia, with minimal side effects.

Targeting androgen receptors with antiandrogen oligonucleotides could effectively treat hair loss.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

This study found that Atractylodes macrocephala Koidz. extract promotes anagen entry and hair regrowth by enhancing dermal papilla cell activity and supporting hair cycle progression in a mouse model.

In this study, a herbal preparation inhibited the conversion of testosterone to DHT and its binding on hair roots in vitro, suggesting potential as an alternative treatment for androgenic alopecia without the safety concerns associated with finasteride.

This study found that the novel IPC analog SIG-1451 may inhibit inflammatory cytokine release in cell-based assays relevant to allergic dermatitis.